Metabolon announces publication of diabetes study in PLoS ONE journal

Metabolon, Inc., leaders in global metabolomics, biomarker discovery and biochemical analysis, announces the publication of "Metabolic Footprint of Diabetes: A Multiplatform Metabolomics Study in an Epidemiological Setting" in PLoS ONE.

“Metabolic Footprint of Diabetes: A Multiplatform Metabolomics Study in an Epidemiological Setting”

Data from Metabolon's non-targeted biochemical profiling platform was combined with data collected from targeted metabolomics platforms to identify metabolic signatures that are associated with Type 2 diabetes. The proof of concept study illustrates the value of using metabolomics to identify biochemical pathways affected by Type 2 diabetes. The authors show that functional metabolomics can contribute to the development of a more sophisticated classification of the disease and lead to optimized diagnosis and treatment options.

Copies of the paper can be accessed from PLoS ONE: http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0013953